ABEO is undervalued; Market has NOT priced in FDA approval news.Looks like a good monthly or longer play for the following reasons:
1. Beginning to see elevated RVOL (although it is Pre) in the hundreds.
2. recent fantastic news, the MAIN drug they are developing received FDA approval, this cannot be understated as a) it makes all previous revenues from quarters irrelevant (as they can now fully market and distribute the treatment, which will fix prior low rev issues, because its an R&D company), b) they were only losing about 40mil a quarter before which again, is actually relatively low compared to other pharma-dev companies (many have like 20mil + burn per quarter).
3. stock is trading at a consolidation region below the gap, for the last few years. (avg range between 3-5$, with some spikes between)
4. managed to stay in the NASDAQ due to a 25/1 reverse split, which many times just continues to crush the company stock, but this one has held steadfast in this lower region for the last three years.
5. Post RS, the price has trended slowly up, with higher lows, and a push back towards the gap, which was rejected in April 2024. Even after this the next lows (May 2024) were still higher, and the rejection from 6.80 region was followed by another higher low (april 2025).
Resistance at around 6.80, and next at the bottom of gap fill at 9.00.
Price has barely moved with the news, and this appears to be a slow burn up until it does a 15%-20% day and pops up on traders screeners.
I'm long on the drop yesterday below 5$.
Popped up on my scanner yesterday and will continue to track this trade. We'll see where it goes by Fall.
Note: we also saw the HIGHEST VOLUME in about 5 years yesterday. With little price movement, this reeks of institutional movement.
0H7R trade ideas
ABEOABEO stock presents one of the best opportunities in the US market, with target prices well above $100. It is an excellent stock for investors. Currently, the stock is in a weekly upward trend and has broken through a strong supply zone from which it had bounced multiple times before. Now, it is pulling back to test this zone as a demand area, gaining momentum to push higher. The next resistance area above is the red supply zone, and if it breaks through, a new high will be set. The target for the new high ranges from $12.70 to $15-$30.
The stock is in the process of forming an inverted head-and-shoulders pattern, which will activate with a break above $9. We are waiting to buy near the range of $5.70 to $4.50,Stop loss 4$, aiming for the higher targets. After reaching $30, we will update the chart.
ABEO Long PositionABEO has a nice Long setup .
Ma cross 32/72 strategy on weekly timeframe
with 1.5 reward to risk ratio .
Entry around 4.78 cents
Stop is at 3.63 cents , which is the low of the bottom of the candle of the MA cross
target is 6.50 cents
, indicators on chart is insane oscillator from Trade oracle all Green ready to roll upside
, Ma cross, 32/72
Abeona Therapeutics Inc.** risky investment opportunity, $200m market capital **
Happy with the risk?
On the above 10-day chart price action has corrected a massive 95% from a high of $20 in early 2018. A number of reasons now exist to be bullish. Why?
1) Bullish divergences. Since the ‘great buy’ signal price action has continued to print lower lows while higher lows are printing with the oscillators. The monthly chart below provides a better overall illustration. Currently 7 oscillators are diverging with price action.
2) RSI resistance. After an extensive period RSI has broken resistance. This is clearly visible on both 10-day and monthly charts.
3) Volume. On the 3-month chart (bottom) volume continues to flow in as price action dips. I’ve not idea why, someone knows something I don’t. Follow the money.
Is it possible for price action to fall further? For sure.
Is it probable? Unlikely. A buy from < $2.80 is excellent.
Good luck!
WW
Monthly chart bullish divergences
3-month chart - volume
ABEO | Bullish All Year | LongAbeona Therapeutics Inc., a clinical-stage biopharmaceutical company, develops gene and cell therapies for life-threatening rare genetic diseases. Its lead program is EB-101, an autologous, gene-corrected cell therapy that is in Phase III clinical trial for recessive dystrophic epidermolysis bullosa. The company also develops ABO-102, an adeno-associated virus (AAV)-based gene therapy for Sanfilippo syndrome type A; ABO-201 to treat CLN3 disease; ABO-401 for the treatment of cystic fibrosis; and ABO-50X for the treatment of genetic eye disorders. In addition, it is developing AAV-based gene therapy through its AIM vector platform programs. The company was formerly known as PlasmaTech Biopharmaceuticals, Inc. and changed its name to Abeona Therapeutics Inc. in June 2015. Abeona Therapeutics Inc. was incorporated in 1974 and is headquartered in New York, New York.
Watch this one!Abeona Therapeutics Inc., a clinical-stage biopharmaceutical company, develops gene and cell therapies for life-threatening rare genetic diseases. Its lead program is EB-101, an autologous, gene-corrected cell therapy that is in Phase III clinical trial for recessive dystrophic epidermolysis bullosa. The company also develops ABO-102, an adeno-associated virus (AAV)-based gene therapy for Sanfilippo syndrome type A; ABO-201 to treat CLN3 disease; ABO-401 for the treatment of cystic fibrosis; and ABO-50X for the treatment of genetic eye disorders. In addition, it is developing AAV-based gene therapy through its AIM vector platform programs. The company was formerly known as PlasmaTech Biopharmaceuticals, Inc. and changed its name to Abeona Therapeutics Inc. in June 2015. Abeona Therapeutics Inc. was incorporated in 1974 and is headquartered in New York, New York.
$ABEO Next Target PTs .60-1 and higher Abeona Therapeutics Inc., a clinical-stage biopharmaceutical company, develops gene and cell therapies for life-threatening rare genetic diseases. Its lead programs include EB-101, an autologous, gene-corrected cell therapy for recessive dystrophic epidermolysis bullosa; ABO-102, an adeno-associated virus-based gene therapy for Sanfilippo syndrome type A; and ABO-101, an AAV-based gene therapy for Sanfilippo syndrome type B. The company also develops ABO-201 to treat CLN3 disease; ABO-401 for the treatment of cystic fibrosis; and ABO-5OX for the treatment of genetic eye disorders. In addition, it is developing AAV-based gene therapy through its AIM vector platform programs. The company was formerly known as PlasmaTech Biopharmaceuticals, Inc. and changed its name to Abeona Therapeutics Inc. in June 2015. Abeona Therapeutics Inc. was founded in 1974 and is headquartered in New York, New York.
follow-up after seeing the chart from @PlanTradePlanMMAccording to its website, it is a fully-integrated gene and cell therapy company at the forefront of the rapidly-advancing field of genetic medicine. Our expertise across R&D, manufacture, and discovery of novel gene and cell therapies has us uniquely positioned to bring new medicines to patients in need.